<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994080</url>
  </required_header>
  <id_info>
    <org_study_id>HR-PLGHC-301</org_study_id>
    <nct_id>NCT04994080</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Three-arm, Parallel Grouping, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Paricalcitol Soft Capsules in the Treatment of Secondary Hyperparathyroidism in Subjects With Stage 3 and Stage 4 Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu Suncadia Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chengdu Suncadia Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy, and safety of Paricalcitol for&#xD;
      secondary hyperparathyroidism with stage 3 and stage 4 chronic kidney disease in adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multi-center, randomized, double-blind, three-arm, parallel grouping, placebo-controlled phase 3 study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with &gt;30% decrease from basline at least twice in mean iPTH during the efficacy assessment phase.</measure>
    <time_frame>0-24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The value of iPTH for each visit</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline of iPTH for each visit</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change percentage of iPTH for each visit;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects whose iPTH has been reduced by more than 30% from baseline at least 4 consecutive times;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change value of blood bone metabolism index from baseline;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change percentage of blood bone metabolism index from baseline;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change value of urine bone metabolism index from baseline;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change percentage of urine bone metabolism index from baseline;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change value in blood calcium from baseline;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change value in blood phosphorus from baseline;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change value in calcium-phosphorus product from baseline;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change value of 24-hour urine calcium from baseline;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change value of 24-hour urine phosphorus from baseline;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change value of 24-hour creatinine clearance rate from baseline;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change value of eGFR from baseline;</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change value in urine calcium/creatinine ratio from baseline.</measure>
    <time_frame>0-24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Treatment group A/B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>Treatment group A: Paricalcitol 1μg QD Treatment group B: Paricalcitol 2μg TIW</description>
    <arm_group_label>Treatment group A/B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment group C: Placebo to match Paricalcitol，QD or TIW</description>
    <arm_group_label>Treatment group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Under care of physician at least 2 months for CKD&#xD;
&#xD;
          2. Not on active Vitamin D and Calcimimetic therapy for at least 4 weeks prior&#xD;
&#xD;
          3. If taking phosphate binders, on a stable regimen at least 4 weeks prior&#xD;
&#xD;
          4. For entry into Pretreatment Phase:&#xD;
&#xD;
             iPTH at least 120 pg/mL GFR of 15-60 mL/min and no dialysis expected for at least 6&#xD;
             months&#xD;
&#xD;
          5. For entry into Treatment Phase:&#xD;
&#xD;
        Average of 2 consecutive iPTH values of at least 150 pg/mL, taken at least 1 day apart (all&#xD;
        values not less than 120 pg/mL) 2 consecutive corrected serum calcium levels between&#xD;
        8.0-10.0 mg/dL 2 consecutive serum phosphorus levels of not more than 5.2 mg/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who had Primary hyperparathyroidism;&#xD;
&#xD;
          2. Subjects with a history of acute renal failure;&#xD;
&#xD;
          3. Subjects with chronic gastrointestinal disease or severe liver disease with clinical&#xD;
             symptoms;&#xD;
&#xD;
          4. Subjects with a history of unstable angina, grade III or IV congestive heart failure,&#xD;
             and/or clinically meaningful arrhythmia;&#xD;
&#xD;
          5. Subjects with serum albumin &lt; 30g/L, serum hemaoglobin &lt; 85g/L, or serum transaminase&#xD;
             higher than 2.5 times the upper limit of nomal;&#xD;
&#xD;
          6. Subjects with a history of malignancy;&#xD;
&#xD;
          7. Subjects who plan to undergo surgery during the study period;&#xD;
&#xD;
          8. Subjects with a history active granulomatous diseases;&#xD;
&#xD;
          9. Subject with a history of alcohol abuse and drug abuse;&#xD;
&#xD;
         10. Human immunodeficiency virus antibody (HIV-Ab), hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis C antibody (HCV-Ab) or Treponema pallidum antibody (TP-Ab) are positive;&#xD;
&#xD;
         11. Subjects who are allergic to the test drug and its ingredients or excipients;&#xD;
&#xD;
         12. Subjects who combined with systemic or systemic diseases that are not suitable for&#xD;
             clinical trials;&#xD;
&#xD;
         13. Subjects who have participated in clinical trials of other drugs or devices;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yin Tong</last_name>
    <phone>+0518-82342973</phone>
    <email>yin.tong@hengrui.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

